Northwest Biotherapeutics (NWBO) Other financing activities (2010 - 2026)

Northwest Biotherapeutics' Other financing activities history runs 16 years deep, the most recent figure standing at $6000.0 for Q1 2026.

• In Q1 2026, Other financing activities fell 64.71% year-over-year to $6000.0; the TTM figure through Mar 2026 stood at $12000.0 (down 95.02% YoY), while the FY2025 annual figure was $23000.0, down 98.5% from the prior year.
• Other financing activities for Q1 2026 stood at $6000.0, roughly flat from $6000.0 in the prior quarter.
• The five-year high for Other financing activities was $5.4 million in Q2 2022, with the low at $6000.0 in Q2 2025.
• The 5-year median for Other financing activities is $180000.0 (2024), against an average of $958733.3.
• The sharpest annual moves came in 2022 and 2025: Other financing activities surged 461.74% in 2022, then tumbled 98.7% in 2025.
• Northwest Biotherapeutics' Other financing activities stood at $1.1 million in 2022, then sank by 89.32% to $119000.0 in 2023, then plunged by 84.87% to $18000.0 in 2024, then slumped by 66.67% to $6000.0 in 2025, then changed by 0.0% to $6000.0 in 2026.
• Business Quant data shows NWBO's Other financing activities at $6000.0 in Q1 2026, $6000.0 in Q2 2025, and $17000.0 in Q1 2025.